Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03951610 · ClinicalTrials.gov registry record · NA
A Dispensing Comparison of a Test Daily 1 Day Lens Against a Control 1 Day Lens.
A NA study of Myopia, sponsored by CooperVision.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
- 2
- Study locations
NCT03951610: Completed NA study of Myopia, sponsored by CooperVision.
NCT03951610 is a NA study of Myopia that has completed, run by CooperVision. The registered enrollment target is 52 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03951610, a NA study of Myopia, has completed, sponsored by CooperVision.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to compare the dispensing performance of somofilcon A test 1 day contact lens against somofilcon A control 1 day contact lens.
Primary Outcome
Centration: Grade degree of Centration (Optimally Centered, Slightly Decentered (\<0.5mm Nasal (N), T (Temporal), S (superior), I (inferior), Extremely Decentered (\>0.5mm N T S I)
Conditions Studied
Interventions
- DEVICE Test lens
- DEVICE Control lens
Study Locations (2)
California
- University Eye Center at Ketchum Health - Anaheim
Indiana
- Clinical Optics Research Lab (CORL) Indiana University School of Optometry, Indiana University - Bloomington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-02-21 |
| Est. Completion | 2019-06-04 |
| Phase | NA |
What the finished NCT03951610 record still lists
NCT03951610 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Test lens is the first listed.
NCT03951610 reports a single indexed study location in California, Indiana.
Frequently Asked Questions
What is clinical trial NCT03951610 about?
NCT03951610 is a clinical study titled "A Dispensing Comparison of a Test Daily 1 Day Lens Against a Control 1 Day Lens.". The purpose of this study is to compare the dispensing performance of somofilcon A test 1 day contact lens against somofilcon A control 1 day contact lens.
What is the current status of trial NCT03951610?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2019-02-21. Estimated completion is 2019-06-04.
What conditions does trial NCT03951610 study?
This clinical trial studies the following conditions: Myopia.
What interventions are being tested in trial NCT03951610?
The interventions under investigation include: Test lens (DEVICE), Control lens (DEVICE).
Who is sponsoring clinical trial NCT03951610?
This trial is sponsored by CooperVision, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03951610 being conducted?
This trial has 2 study locations across California, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03951610's enrollment target sits among peer trials
52 65th of 90 higher than 25 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI